CR9898A - Derivados de prolinamida como moduladores del canal de sodio - Google Patents

Derivados de prolinamida como moduladores del canal de sodio

Info

Publication number
CR9898A
CR9898A CR9898A CR9898A CR9898A CR 9898 A CR9898 A CR 9898A CR 9898 A CR9898 A CR 9898A CR 9898 A CR9898 A CR 9898A CR 9898 A CR9898 A CR 9898A
Authority
CR
Costa Rica
Prior art keywords
modulators
sodium channel
prolinamide derivatives
prolinamide
derivatives
Prior art date
Application number
CR9898A
Other languages
English (en)
Inventor
Giuseppe Alvaro
Markus Bergauer
Riccardo Giovannini
Roberto Profeta
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0520581A external-priority patent/GB0520581D0/en
Priority claimed from GB0523045A external-priority patent/GB0523045D0/en
Priority claimed from GB0603900A external-priority patent/GB0603900D0/en
Priority claimed from GB0618336A external-priority patent/GB0618336D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CR9898A publication Critical patent/CR9898A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La invencion provee un compuesto de formula (I): un solvato, sal, o profarmaco del mismo, util en el tratamiento de enfermedades y condiciones mediadas por la modulacion de los canales de sodio regulados por voltaje dependiente del uso.
CR9898A 2005-10-10 2008-04-18 Derivados de prolinamida como moduladores del canal de sodio CR9898A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0520581A GB0520581D0 (en) 2005-10-10 2005-10-10 Novel compounds
GB0523045A GB0523045D0 (en) 2005-11-11 2005-11-11 Novel compounds
GB0603900A GB0603900D0 (en) 2006-02-27 2006-02-27 Novel compounds
GB0618336A GB0618336D0 (en) 2006-09-18 2006-09-18 Novel compounds

Publications (1)

Publication Number Publication Date
CR9898A true CR9898A (es) 2008-07-29

Family

ID=37546777

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9898A CR9898A (es) 2005-10-10 2008-04-18 Derivados de prolinamida como moduladores del canal de sodio

Country Status (20)

Country Link
US (2) US7655693B2 (es)
EP (1) EP1934177B8 (es)
JP (1) JP5139305B2 (es)
KR (1) KR101282464B1 (es)
AR (1) AR056575A1 (es)
AT (1) ATE556049T1 (es)
AU (1) AU2006301470B2 (es)
BR (1) BRPI0616944B8 (es)
CA (1) CA2625642C (es)
CR (1) CR9898A (es)
EA (1) EA015736B1 (es)
ES (1) ES2387405T3 (es)
IL (1) IL192627A0 (es)
MA (1) MA29817B1 (es)
NO (1) NO20082145L (es)
NZ (1) NZ567051A (es)
PE (1) PE20070592A1 (es)
PL (1) PL1934177T3 (es)
TW (1) TW200730494A (es)
WO (1) WO2007042239A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143306B2 (en) * 2005-10-10 2012-03-27 Convergence Pharmaceuticals Limited Methods of treating bipolar disorders
EP1943216B1 (en) * 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators
GB0701365D0 (en) * 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) * 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
WO2011015537A1 (en) * 2009-08-05 2011-02-10 Glaxo Group Limited Co-therapy for the treatment of epilepsy and related disorders
SI2477964T1 (sl) * 2009-09-14 2015-10-30 Convergence Pharmaceuticals Limited Postopek za pripravo derivatov alfa-karboksamida
EP2681200A4 (en) 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
JP6577479B2 (ja) 2014-02-27 2019-09-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｎａｖ チャンネル阻害剤としてのヘテロ環化合物及びその使用
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
US10421716B2 (en) 2014-12-23 2019-09-24 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide pyrrolidine derivatives
BR112019008913A2 (pt) * 2016-11-02 2019-08-06 Biogen Ma Inc novo regime de dosagem
MX2019013758A (es) * 2017-05-19 2020-07-20 Biogen Ma Inc Formas cristalinas novedosas.
JP2020536870A (ja) * 2017-10-05 2020-12-17 バイオジェン インコーポレイテッド アルファカルボキサミドピロリジン誘導体の調製方法
SG11202002707VA (en) 2017-10-10 2020-04-29 Biogen Inc Process for preparing spiro derivatives
BR112020021101A2 (pt) * 2018-04-16 2021-02-23 Biogen Ma Inc métodos de tratamento da dor neuropática
CA3136536A1 (en) * 2019-04-10 2020-10-15 Biogen Ma Inc. Process for preparing alpha-carboxamide pyrrolidine derivatives
AU2020272878A1 (en) * 2019-04-10 2021-12-02 Biogen Inc. Processes for preparing alpha-carboxamide pyrrolidine derivatives
US20230105795A1 (en) * 2020-01-30 2023-04-06 Mohammad JAVED Combination drug therapies for cns disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US6201016B1 (en) 1994-06-27 2001-03-13 Cytomed Incorporated Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
US6136131A (en) * 1998-06-02 2000-10-24 Instrument Specialties Company, Inc. Method of shielding and obtaining access to a component on a printed circuit board
PT1173169E (pt) 1999-03-26 2010-08-19 Euro Celtique Sa Pirazoles, imidazoles, oxazoles, tiazoles e pirroles substituídos com arilo
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
GB0115517D0 (en) * 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
TW200404796A (en) * 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
PE20050077A1 (es) 2002-09-20 2005-03-01 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil-eter
AR044503A1 (es) 2003-03-18 2005-09-14 Merck & Co Inc Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
JP2006522130A (ja) 2003-04-03 2006-09-28 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャンネル遮断薬としてのビアリール置換ピラゾール
US20070060584A1 (en) * 2003-04-18 2007-03-15 Chakravarty Prasun K Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
EP1524265A1 (en) * 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors
WO2005100334A1 (en) * 2004-04-14 2005-10-27 Pfizer Products Inc. Dipeptidyl peptidase-iv inhibitors
WO2006119390A1 (en) 2005-05-04 2006-11-09 Vertex Pharmaceuticals Incorporated Pyridines useful as modulators of ion channels
EP1877385A1 (en) 2005-05-04 2008-01-16 Vertex Pharmaceuticals Incorporated Pyrimidines and pyrazines useful as modulators of ion channels
JP2008540665A (ja) 2005-05-19 2008-11-20 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なビアリール
AR058805A1 (es) * 2005-09-09 2008-02-27 Smithkline Beecham Corp Derivados biciclicos de piridina utiles como agentes antipsicoticos
EP1943216B1 (en) * 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators
TW200728258A (en) * 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
GB0701365D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0701366D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
CA2625642C (en) 2013-12-24
ATE556049T1 (de) 2012-05-15
TW200730494A (en) 2007-08-16
BRPI0616944B8 (pt) 2021-05-25
NO20082145L (no) 2008-05-07
US20100105754A1 (en) 2010-04-29
IL192627A0 (en) 2011-08-01
EA200801054A1 (ru) 2008-08-29
AU2006301470B2 (en) 2012-06-14
CA2625642A1 (en) 2007-04-19
ES2387405T3 (es) 2012-09-21
US8153681B2 (en) 2012-04-10
BRPI0616944B1 (pt) 2020-04-14
AR056575A1 (es) 2007-10-10
US7655693B2 (en) 2010-02-02
JP2009511519A (ja) 2009-03-19
EP1934177B1 (en) 2012-05-02
BRPI0616944A2 (pt) 2011-07-05
EP1934177A1 (en) 2008-06-25
US20080280969A1 (en) 2008-11-13
KR101282464B1 (ko) 2013-07-04
JP5139305B2 (ja) 2013-02-06
NZ567051A (en) 2011-03-31
PE20070592A1 (es) 2007-06-23
AU2006301470A1 (en) 2007-04-19
EA015736B1 (ru) 2011-10-31
KR20080059296A (ko) 2008-06-26
MA29817B1 (fr) 2008-09-01
PL1934177T3 (pl) 2013-03-29
EP1934177B8 (en) 2012-09-05
WO2007042239A1 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
CR9898A (es) Derivados de prolinamida como moduladores del canal de sodio
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
CO2022008969A2 (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
AR077252A1 (es) Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
CR11470A (es) Compuestos organicos
CL2011001658A1 (es) Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor.
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
ECSP066392A (es)
CY1113924T1 (el) Ενωσεις καρβαζολης και θεραπευτικες χρησεις των ενωσεων
ATE551333T1 (de) Biphenylderivate als modulatoren von spannungsabhängigen ionenkanälen
CR11045A (es) Mezclas activas pesticidas que comprenden compuestos de aminotiazolina
NI200900040A (es) Derivados de quinazolinona 5-substituidos como agentes antitumorales.
ECSP088412A (es) Derivados de pirazina como moduladores de canal de sodio en el tratamiento del dolor
ECSP12011625A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
MY150865A (en) Insecticidal aryl pyrrolidines
PA8595901A1 (es) "n-arilheterociclos sustituidos, procedimientos para su preparacion, y su empleo como medicamentos
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
ECSP088306A (es) Agentes para prevenir y tratar los trastornos que involucran la modulación de los receptores ryr
CR8986A (es) Isoxazoles sustituidos como fungicidas
EA200870497A1 (ru) Бензимидазольные модуляторы vr1
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
TW200728258A (en) Novel compounds
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
PA8792401A1 (es) Fenilendiaminas
CO6531479A2 (es) Derivados de espirolactama y uso de los mismos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)